Prof. Dr. Sebastian Bauer is a leading oncologist and academic researcher at the University of Duisburg-Essen, affiliated with the Medical Faculty and the West German Cancer Center (WTZ) at University Hospital Essen. He leads the Translational Sarcoma Research group, focusing on soft-tissue sarcomas, particularly gastrointestinal stromal tumors (GIST). His work integrates molecular oncology, preclinical modeling, and clinical trials to advance targeted therapies. Research Interests: His research spans translational cancer research , oncogenetic signaling pathways , tyrosine kinase inhibitors , preclinical cancer models , and drug development . He investigates mechanisms of resistance in GIST and evaluates novel therapeutic agents in clinical settings. The recent publication trends highlight a strong focus on targeted therapies (e.g., avapritinib, ripretinib), biomarker discovery (ctDNA, neoantigens), and combination therapies in sarcomas. His work frequently appears in high-impact journals such as Nature Communications and Clinical Cancer Research , reflecting significant contributions to clinical oncology and molecular therapeutics. Scientific Awards: No specific awards mentioned in the provided text. Advising and Grants: While specific student names are not listed, Prof. Bauer leads a research group and participates in PhD programs through the ZMB (Center for Molecular Biomedicine), indicating active mentoring. His research is supported by national and international collaborations, including DFG, EU programs, and industry partnerships, particularly in drug licensing and clinical trials. Labs and Teams: He heads the Translational Sarcoma Research group at WTZ Essen, collaborating closely with institutions like TU Dortmund and the Max Planck Institute. His team works on drug discovery, proteogenomics, and clinical trial design, contributing to the development of novel therapies for rare cancers.
جستجوی استاد راهنمای دانشگاهی
برای مسیر پژوهشیتان، استاد راهنما، استاد دانشگاه و پژوهشگر مناسب را پیدا کنید و با آنها ارتباط بگیرید.
نمایش ۱-۵ از ۵ استاد راهنما
اطلاعات پروفایلها از صفحات عمومی دانشگاهها گرفته شده و ممکن است بهروز نباشد.
Professor Sebastian Bauer is a Faculty of the University Hospital Essen, leading the Translational Sarcoma Research Group at the West German Cancer Center (WTZ-F). His research focuses on oncogenetic signaling pathways in soft-tissue sarcomas (GIST) , evaluation of targeted small molecule kinase inhibitors , development of GIST and sarcoma cell line models , and advanced preclinical diagnostic techniques . He collaborates with institutions like the West German Biobank Essen, Departments of Visceral and Tumororthopedic Surgery, and the Institute of Pathology to establish patient-derived models. Research Trends : His most recent publications (2024-2015) analyze KIT/PDGFRA mutation dynamics , resistance mechanisms to tyrosine kinase inhibitors , CRISPR/Cas9-based research models , and novel therapeutic strategies for sarcomas . Key keywords include GIST , oncogenetic signaling , kinase inhibitors , genomic heterogeneity , apoptosis regulation , and precision medicine . Scientific Collaborations : Bauer works with academic partners in Chemical biology Cancer genomics Molecular pharmacology to develop novel inhibitors and translate findings into clinical protocols. Advising and Grants : He mentors PhD student Stephanie Wesemann and secures funding from The David Foundation Deutsche Forschungsgemeinschaft (DFG) for projects like CRISPR/Cas9 pipelines and resistance mutation screening . Labs and Teams : Leads a multidisciplinary team at WTZ-F R0.013, including lab head Dr. Thomas Mühlenberg, postdocs Drs. Susanne Grunewald and Dawid Krzeciesa, junior scientists Alena Spieckermann and Yanosan Thavarasa, and technical assistants Miriam Christoff and others. The group also participates in the Sarcoma Center Essen and annual Sarcomatour bicycle fundraiser.
Prof. Dr. Nikolas Christian Cornelius von Bubnoff is Director of the Department of Hematology and Oncology at the University Medical Center Schleswig-Holstein (UKSH), Lübeck campus, and a leading figure at the University Cancer Center Schleswig-Holstein (UCCSH). He is affiliated with the Faculty of Medicine at the University of Lübeck, where he contributes to clinical care, research, and academic education. His leadership spans both clinical and research domains, particularly in advancing personalized oncology and molecular tumor boards. His research focuses on improving the molecular understanding of tumor diseases to develop novel targeted therapies and overcome treatment resistance. Key areas include liquid biopsy for circulating tumor DNA (ctDNA), biomarker development, and clinical decision support via molecular tumor boards. His team investigates gastrointestinal stromal tumors (GIST), melanoma, pancreatic cancer, and hematologic malignancies using digital PCR and NGS techniques. Prof. von Bubnoff is actively involved in clinical trials, serving as a principal investigator in early-phase (Phase I/II) studies and multicenter research through the German GISG group. He promotes academic training by supervising bachelor’s, master’s, and doctoral theses in medicine, molecular life sciences, and biology. He also leads initiatives in process quality improvement at tumor centers and translational biomarker projects. Scientific contributions include work on predictive biomarkers, therapy response monitoring, and rare cancers. Awards and fellowships are not specified in the available text. Executive Board, University Cancer Center Schleswig-Holstein (UCCSH) Director, Department of Hematology and Oncology, UKSH Lübeck Professor, Faculty of Medicine, University of Lübeck He leads a multidisciplinary team within the Molecular Tumor Board, collaborating with pathologists, geneticists, and systems biologists to deliver individualized treatment strategies. The department is part of the Center for Personalized Medicine - Oncology and hosts specialized labs for hematological diagnostics and translational research.
Prof. Dr. med. Cyrus Khandanpour is a full Professor for Translational Cancer Research and serves as Deputy Director and Senior Consultant at the Department of Hematology and Oncology at the University Medical Center Schleswig-Holstein (UKSH), Lübeck campus, affiliated with the University of Lübeck. He is also the Executive Director of the University Cancer Center Schleswig-Holstein (UCCSH), where he leads initiatives in precision medicine and translational oncology. His work bridges clinical care and research, focusing on molecular mechanisms of cancer and innovative diagnostics. The focus of his research lies in improving the molecular understanding of tumor diseases, particularly through liquid biopsy and circulating tumor DNA (ctDNA) analysis. His team investigates the predictive and prognostic value of ctDNA in solid tumors, especially in gastrointestinal stromal tumors (GIST), within multicenter clinical studies. Additional research themes include therapy resistance, biomarker development, germline variants (e.g., GFI1-36N in AML), and decision support via Molecular Tumor Boards. His recent public engagement includes a lecture titled "2050: Will cancer become history?!" at the Science Night of the University of Lübeck (2023) and participation in the annual meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology (2022), where he discussed precision medicine and novel therapies for multiple myeloma. Although no individual articles are listed, his research output likely spans translational oncology, molecular diagnostics, and clinical cancer research. Prof. Khandanpour actively supports academic training by supervising bachelor’s, master’s, and doctoral theses in medicine, molecular life sciences, and biology, particularly in clinical biomarker projects. He collaborates extensively within the University Cancer Center Schleswig-Holstein and with the Kiel campus of the University Cancer Center Hamburg (UCCH), fostering regional and national partnerships. He is involved in clinical trial leadership, offering patients access to cutting-edge therapies through ethics-approved, controlled studies. His leadership roles include strategic development of cancer care pathways, integration of molecular diagnostics into clinical practice, and advancing personalized treatment models.
- Translational Cancer Research
- Hematology
- Oncology
- +۱۲ مورد دیگر
Prof. Dr. Siavosh Mahboobi is a faculty member at the University of Regensburg , affiliated with the Institute of Pharmacy and working in the Pharmaceutical/Medicinal Chemistry I department. His research focuses on molecular mechanisms of cancer and the development of targeted therapies. Signal transduction pathways in cancer FLT3 and PDGFR tyrosine kinase inhibitors HDAC and tubulin inhibition strategies EGFR-targeted therapies 5-HT receptor agonists/antagonists His work emphasizes the design of small molecules that disrupt cancer-related signaling. He has received the PHOENIX Pharmaceutical Sciences Award (2011) for his contributions to anticancer drug development.